Dr Voss Application of Updated KEYNOTE-564 Data
July 16th 2024Martin Voss, MD, elaborates on the impact of the KEYNOTE-564 trial and its recently presented data on the management of renal cell carcinoma, highlighting how these findings have influenced treatment decisions and patient care strategies.
Read More
Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
July 16th 2024Wenxin (Vincent) Xu, MD, presents the findings from the phase 3 CONTACT-03 trial, which compared the efficacy of atezolizumab in combination with cabozantinib versus cabozantinib alone in patients with inoperable advanced renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.
Read More
Dr Voss Shares Highlights from the COSMIC-313 and LITESPARK-024 Trials
July 2nd 2024Martin Voss, MD, discusses the subgroup analysis of the COSMIC-313 study, which investigated the combination of nivolumab, ipilimumab, with or without cabozantinib (nivo + ipi +/- cabo), focusing on the potential advantages this treatment approach may offer for patients with intermediate to high-risk renal cell carcinoma (RCC).
Read More
Dr Wulff-Burchfield Reviews CheckMate 214 and CheckMate 9ER
June 25th 2024The panelists examine the latest findings from the CheckMate 214 trial, which assessed the combination of nivolumab and ipilimumab (nivo + ipi) as a first-line treatment for advanced renal cell carcinoma, focusing on efficacy, safety, and quality of life outcomes.
Read More
Treatment Selection in the Frontline Setting of Advanced Clear Cell RCC
June 25th 2024Dr. Pedro Barata, MD, MSc, provides an overview of advanced clear cell renal cell carcinoma (RCC), discussing its typical presentation, the role of systemic therapies, and summarizing the first-line treatment options available for this condition.
Read More
Practical Considerations in Selecting Therapy for Metastatic CRPC
Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.
Read More
What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?
Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
Read More
Metastatic CRPC: Practical Selection and Use of PARP Inhibitors
Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.
Read More
An Overview of PARP Inhibition in Metastatic CRPC
Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.
Read More
PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition
Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.
Read More